Abstract
The ongoing antifungal therapy for pregnant patients is one of the poorly studied sections of pharmacotherapy, and in particular, clinical pharmacology. As it is known, large clinical studies are not conducted in pregnant women for ethical reasons. In addition, when prescribing antifungal drugs to pregnant women, doctors often forget that the physiological changes that occur in a woman's body can lead to changes in the pharmacokinetics of these drugs and, consequently, to a change in their effectiveness and safety, which is fraught with consequences not only for the fetus, but also for mother. The purpose of the studies is to evaluate the frequency and quality of using antifungal agents during pregnancy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
